Viralytics Combination
Edison | Nov 27, 2015 01:58AM ET
Combination trials gather momentum
Viralytics is escalating combination trials of its Cavatak oncolytic virotherapy with immune checkpoint inhibitors (ICI), adding a collaboration with Merck (N:MRK) to study IV Cavatak combined with Keytruda in advanced lung and bladder cancers to its portfolio of ongoing trials combining intralesional Cavatak with Keytruda or Yervoy in melanoma patients. Cavatak has the potential to markedly improve the proportion of patients who respond to ICI therapy and we expect it to continue to attract attention from big pharma. We value Viralytics at A$192m or A$1.04 per share.
Viralytics and Merck collaborate on combination trial
Viralytics and Merck will collaborate on a clinical trial combining intravenous (IV) Cavatak with Merck’s marketed anti-PD1 checkpoint inhibitor Keytruda (pembrolizumab) in lung and bladder cancer. The Phase Ib trial, which we expect to begin in H116, will be the second stage of Viralytics’ ongoing STORM trial.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.